[Health Technology Assessment of meningococcal B vaccine (Trumenba®) in adolescent in Italy]

J Prev Med Hyg. 2019 Dec 19;60(3 Suppl 2):E1-E94. doi: 10.15167/2421-4248/jpmh2019.60.3s2. eCollection 2019 Dec.
[Article in Italian]
No abstract available

MeSH terms

  • Adolescent
  • Cost-Benefit Analysis
  • Health Knowledge, Attitudes, Practice
  • Health Literacy
  • Humans
  • Italy / epidemiology
  • Meningitis, Meningococcal / diagnosis
  • Meningitis, Meningococcal / epidemiology
  • Meningitis, Meningococcal / prevention & control*
  • Meningitis, Meningococcal / therapy
  • Meningococcal Infections / diagnosis
  • Meningococcal Infections / epidemiology
  • Meningococcal Infections / prevention & control
  • Meningococcal Infections / therapy
  • Meningococcal Vaccines / economics
  • Meningococcal Vaccines / therapeutic use*
  • Neisseria meningitidis, Serogroup B / immunology*
  • Patient Acceptance of Health Care
  • Technology Assessment, Biomedical
  • Vaccination Refusal

Substances

  • Meningococcal Vaccines